Skip to content

Monthly Archives August 2007

Medical technology definitions and markets get blurry

Time was when a device was a device, a drug was a drug and biotech was . . . well, still in R&D. If it walks like a duck, sounds like a duck and looks like a duck, it’s a duck — or is it? You have to make certain that you carefully [...]

Posted 30 August 2007 † P. Driscoll § biotech § cardiology § market data § medtech § orthopedic § surgery ‡ Comments (3) ° Tagged: , , , , ,

Obesity Drug and Device Markets

The current worldwide value of drugs and devices for the treatment of obesity stands at $750 million, representing a minor share of the combined potential market expected for these products over the next decade as rates of obesity incidence and prevalence surge and as recognition of its healthcare cost drives development of effective [...]

Posted 28 August 2007 † P. Driscoll § gastroenterology § market data § medtech § obesity § surgery ‡ Comments (3) ° Tagged: , , , ,

Surgical Procedures Worldwide with Potential for Use of Hemostats, Med/Surg Glues & Sealants and Adhesion Prevention

Surgical wounds are projected to increase in number at an annual rate of 3%, but overall the severity and size of surgical wounds will continue to decrease over the next five years as a result of the continuing trend toward minimally invasive surgery.

Surgical procedures generate a large number of uncomplicated acute wounds with uneventful healing, [...]

Posted 16 August 2007 † P. Driscoll § cardiology § gastroenterology § market data § medtech § neurology § orthopedic § surgery § wound management ‡ Comments (1) ° Tagged: , , , , , , ,

Bone and Other Allografts Worldwide

Allografts are the main “traditional” orthopaedic biomaterials. This market segment includes bone allografts (fresh, or freeze-dried bone; also demineralized bone) and soft-tissue allografts, including cartilage, tendons and meniscus.
The global market for all allografts was $1.5 billion in 2006, with bone allografts contributing half of that, soft-tissue allografts $500 million, and demineralized bone the remaining [...]

Posted 08 August 2007 † P. Driscoll § biotech § market data § medtech § orthopedic ‡ Comments (0) ° Tagged: , , ,

Obesity Drugs Take Hit; Market Potential Undaunted

The worldwide market for obesity drugs represents an extremely attractive opportunity, even more so now that Sanofi-Aventis rimonabant has failed to gain FDA approval.
A surprise to no one, the incidence of obesity and morbid obesity is on the rise, pushing an aggregate prevalence in excess of 300 million patients globally, and outpaced in growth only [...]

Posted 07 August 2007 † P. Driscoll § gastroenterology § medtech § obesity § surgery ‡ Comments (0) ° Tagged: , , ,